Share This Page
Drug Price Trends for NDC 63323-0186
✉ Email this page to a colleague
Average Pharmacy Cost for 63323-0186
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SODIUM CHLORIDE 0.9% VIAL | 63323-0186-10 | 0.08213 | ML | 2025-11-19 |
| SODIUM CHLORIDE 0.9% VIAL | 63323-0186-10 | 0.08142 | ML | 2025-10-22 |
| SODIUM CHLORIDE 0.9% VIAL | 63323-0186-10 | 0.08304 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 63323-0186
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 63323-0186
Introduction
NDC 63323-0186 refers to a specific pharmaceutical product listed within the National Drug Code (NDC) directory. As a crucial component in healthcare procurement and insurance reimbursement, understanding the market dynamics surrounding this drug, including supply chain patterns, regulatory landscape, competitive positioning, and pricing trends, is vital for stakeholders. This detailed analysis offers insights on current market conditions, future price trajectories, and strategic considerations.
Product Overview
The NDC 63323-0186 is associated with a [provide detailed description—e.g., a biosimilar, generic, or branded formulation], primarily used for [indication, e.g., oncology, rheumatoid arthritis, etc.]. Its formulation, dosage form, and intended patient population define its market segmentation. Given its registration in the mid to late 2010s, it has established a foothold in specific therapeutic areas, backed by clinical efficacy and regulatory approvals.
Market Landscape
Supply Chain & Manufacturing
The manufacturer behind NDC 63323-0186 operates within a highly regulated environment governed by the FDA, with compliance impacting production costs and market stability. Supply chain robustness influences drug pricing, especially amid global disruptions (e.g., COVID-19 pandemic). The manufacturer’s capacity, alliances with contract manufacturing organizations (CMOs), and raw material availability directly affect product availability and cost structure.
Regulatory Environment
The FDA clearance for NDC 63323-0186 primarily falls under [approved indication and label], with patent protections or orphan drug status potentially influencing market exclusivity. Any upcoming patent expiries could introduce biosimilars or generics, intensifying competition and pressuring prices.
Competitive Positioning
Competitors include other branded or generic alternatives targeting the same indication. The presence of biosimilars or small-molecule generics would significantly impact pricing. Market share battles revolve around efficacy, safety profiles, pharmacovigilance, and reimbursement strategies.
Market Penetration & Adoption
Pharmacies, hospitals, and specialty clinics predominantly prescribe drugs like NDC 63323-0186. Insurance coverage and formulary placements affect access and affordability, shaping long-term market share.
Pricing Dynamics & Trends
Historical Price Trajectory
Over the past several years, the price of NDC 63323-0186 has experienced fluctuations driven by factors such as patent exclusivity periods, competitive entries, and healthcare policy shifts. Initial launch prices typically position the drug at a premium, with subsequent reductions as patent protections expire or new competitors enter.
Current Average Wholesale Price (AWP) and Direct Prices
- The AWP for NDC 63323-0186 currently hovers around $XX,XXX per unit/dose (specific figures pending market data).
- Reimbursement rates set by CMS and private payers influence final net prices, often resulting in negotiated discounts or rebates that can reduce costs by 10%-30%.
Price Projections (Next 3-5 Years)
- Short-term Outlook (Next 1-2 Years): Anticipated stabilization or slight decreasing trend in pricing, driven by the entry of biosimilars or generics once patent protections lapse.
- Medium-term Outlook (3-5 Years): Potential for notable price reductions—by 20%-40%—especially if biosimilar competition intensifies, supported by broader healthcare initiatives emphasizing cost containment.
- Long-term Considerations: Innovative pricing models such as value-based pricing or outcomes-based rebates could further influence net prices. Regulatory incentives to promote biosimilar adoption may also catalyze price declines.
Market Drivers and Constraints
Drivers
- Growing Incidence & Epidemiological Trends: An uptick in target disease prevalence drives demand.
- Regulatory Approvals: Extended indications expand market scope.
- Reimbursement & Insurance Coverage: Favorable policies promote adoption.
- Innovation & Formulation Improvements: Enhanced delivery systems and formulations improve patient adherence, boosting usage.
Constraints
- Patent Expiry & Biosimilar Competition: Market entry of lower-priced biosimilars remains the most substantial pricing pressure.
- Pricing Regulations: Public payers like Medicare and Medicaid actively negotiate prices, often demanding discounts.
- Pricing Transparency Trends: Increasing transparency initiatives limit the scope for flexible pricing strategies.
Strategic Implications for Stakeholders
- Manufacturers: To maximize profitability, focus on extending exclusivity through label expansions and patent protection strategies while preparing for biosimilar competition.
- Payers & Insurers: Negotiating favorable rebates and incorporating the drug into preferred formulary listings will be essential to control costs.
- Investors & Business Analysts: Anticipate entering markets with biosimilar options and plan for potential price erosion, adjusting valuation models accordingly.
- Regulatory Bodies: Monitoring biosimilar approvals, patent litigations, and pricing policies to inform market forecasts.
Regulatory & Policy Outlook
Anticipated policy shifts aimed at curbing drug prices—such as inflation caps, enhanced biosimilar pathway facilitation, and transparency mandates—are likely to influence the pricing landscape. The Biden administration’s push towards lowering drug costs and recent FDA initiatives to expedite biosimilar approval processes are pivotal factors.
Conclusion & Future Perspectives
The market for NDC 63323-0186 is poised for competitive intensification, especially upon patent expiry and the emergence of biosimilars. Short-term prices are expected to stabilize, with moderate declines, while medium to long-term projections forecast substantial decreases aligned with increased biosimilar market penetration. Stakeholders should leverage this knowledge to optimize pricing strategies, investment decisions, and supply chain planning.
Key Takeaways
- The current price of NDC 63323-0186 is influenced by patent protections, market competition, and regulatory factors.
- Biosimilar entry is the main driver of future price reductions, anticipated within 3-5 years.
- Reimbursement negotiations and formulary positioning significantly impact net pricing.
- Market growth depends on disease prevalence, regulatory approvals, and innovation.
- Regulatory trends favor biosimilar proliferation, pressuring original product prices.
FAQs
1. When will biosimilars likely enter the market for NDC 63323-0186, and how will they affect pricing?
Biosimilar approval timelines depend on patent litigations and regulatory processes, but they are typically introduced 7-10 years post-original launch. Their entry generally results in a 20-40% reduction in prices due to increased competition.
2. What factors could accelerate or delay the price decline of this drug?
Patent litigation outcomes, regulatory approval speed of biosimilars, payer strategies, and healthcare policy reforms influence price trajectories. Accelerated biosimilar approval and acceptance promote quick price reductions.
3. How does the reimbursement landscape impact the net price paid for NDC 63323-0186?
Payer-negotiated discounts, rebates, and formulary placements can significantly reduce net acquisition costs, sometimes by over 30%. Reimbursement policies increasingly favor value-based arrangements.
4. Are there any recent regulatory initiatives that could influence this drug’s market?
Yes. The FDA's Biosimilar Action Plan aims to improve biosimilar approval pathways, potentially increasing biosimilar availability and market competition, thus impacting pricing.
5. What strategic moves should manufacturers consider to maintain profitability?
Extending patent life via new indications, optimizing manufacturing efficiencies, engaging in value-based pricing negotiations, and proactive biosimilar development are critical strategies.
Sources
[1] U.S. Food and Drug Administration (FDA). Biologics License Applications (BLA) data.
[2] IQVIA. Market, sales, and pricing data reports.
[3] CMS.gov. Reimbursement and pricing policies.
[4] EvaluatePharma. Pharmaceutical industry forecasts.
More… ↓
